UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 2)*


MOLECULAR INSIGHT PHARMACERUTICALS, INC.
(Name of Issuer)

Common Stock
(Title of Class of Securities)


60852M104
(CUSIP Number)


March 25, 2011
(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:
o Rule 13d-1(b)
X Rule 13d-1(c)
o     Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a
reporting person?s initial filing on this form with respect to
the subject class of securities, and for any subsequent
amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page
shall not be deemed to be ?filed? for the purpose of Section 18
of the Securities Exchange Act of 1934 (?Act?) or otherwise
subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the
Notes).





Page 2

Persons who respond to the collection of information contained
in this form are not required to respond unless the form
displays a currently valid OMB control number.

13G
CUSIP No. 60852M104

1.	 Names of Reporting Persons.

Beaver Creek Fund, Ltd

I.R.S. Identification Nos. of above persons (entities only)

13-26559998

2.  Check the Appropriate Box if a Member of a Group (See
Instructions)
(a) o
(b) X

3.  SEC Use Only
4.	Citizenship or Place of Organization
Cayman Islands

   Number of Shares Beneficially
   Owned by Each Reporting
   Person

With:
5.  Sole Voting Power      -0-


6.  Shared Voting Power     288,074


7.  Sole Dispositive Power     -0-


8.  Shared Dispositive Power     288,074



Page 3 of 8


9.  Aggregate Amount Beneficially Owned by Each Reporting Person
288,074

10.  Check if the Aggregate Amount in Row (11) Excludes Certain
Shares (See Instructions)
o
11. Percent of Class Represented by Amount in Row (11)
1.14% based on 25,268,327 shares outstanding as of November 4,
2009

12. Type of Reporting Person (See Instructions)
OO



CUSIP No. 60852M104


3.	 Names of Reporting Persons.

Andrew R. Midler

I.R.S. Identification Nos. of above persons (entities only)

2.  Check the Appropriate Box if a Member of a Group (See
Instructions)
(a) o
(b) X

3.  SEC Use Only
   Number of
Shares

Beneficially
   Owned by
   Each
Reporting
   Person
With:
5.  Sole Voting Power      -0-


Page 4 of 8

6.  Shared Voting Power     288,074


7.  Sole Dispositive Power     -0-


8.  Shared Dispositive Power     288,074


9.  Aggregate Amount Beneficially Owned by Each Reporting Person
288,074

10.  Check if the Aggregate Amount in Row (11) Excludes Certain
Shares (See Instructions)
o
11. Percent of Class Represented by Amount in Row (11)
1.14% based on 25,268,327 shares outstanding as of November 4,
2009

12. Type of Reporting Person (See Instructions)
IN



13G
CUSIP No. 60852M104

ITEM 1.
      (a) Name of Issuer:
      	Molecular Insight Pharmaceuticals, Inc. (the ?Issuer?)

      (b) Address of Issuer's Principal Executive Offices:
      	160 Second Street, Cambridge, MA 02142

ITEM 2.
      (a) Name of Person Filing:
      	(i)   Beaver Creek Intermediate Fund, Ltd. (?BCI?)

      	(ii)   Andrew R. Midler (?Mr. Midler?)

      (b) Address of Principal Business Office, or if None,
Residence:
      	The address of the principal business office of each

Page 5 of 8

of the Reporting Persons is One Market Plaza, Steuart Tower, Ste
1400, San Francisco, CA 94105

      (c) Citizenship:

      (i)  BCI is a Cayman Island limited company;


      	(ii)  Mr. Midler is a citizen of the United States of
America

      (d) Title of Class of Securities:
      	Common Stock

      (e) CUSIP Number:
      	60852M104

ITEM 3.  IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b)
OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

	This Item 3 is not applicable

ITEM 4. OWNERSHIP.

Provide the following information regarding the aggregate number
and percentage of the class of securities of the issuer
identified in Item 1.

      (a) Amount beneficially owned:
      	As of April 18, 2011 each of Beaver Creek Ltd
and Mr. Midler may be deemed to be the beneficial owner of
288,074 Shares

      (b) Percent of class:
      	The number of Shares which each of BCI and
Mr. Midler maybe deemed to be the beneficial owner
constitutes approximately 1.14% of the total number of Shares
outstanding (based upon information provided by the Issuer its
most recent filed quarterly report on Form 10-Q, there were
25,268,327 shares outstanding as of November 4, 2009).

      (c) Number of shares as to which such person has:

	      BCI:
Page 6 of 8


 (i)  Sole power to vote or to direct the vote
         -0-

      (ii) Shared power to vote or to direct the vote
         288,074

      (iii) Sole power to dispose or to direct the disposition of
      	   -0-


      (iv)Shared power to dispose or to direct the disposition of
      	288,074

      Mr. Midler
      (i)  Sole power to vote or to direct the vote
         -0-

      (ii) Shared power to vote or to direct the vote
         288,074

      (iii) Sole power to dispose or to direct the disposition of
      	   -0-


      (iv)Shared power to dispose or to direct the disposition of
      	   288,074


ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

	This item 5 is not applicable

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF
ANOTHER
PERSON.

      This item 6 is not applicable

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY
WHICH ACQUIRED THE     SECURITY BEING REPORTED ON BY THE PARENT
HOLDING COMPANY.

      This item 7 is not applicable

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE
GROUP.

	See disclosure of Item 2 hereof.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

      This item 9 is not applicable

ITEM 10. CERTIFICATIONS.

      The following certification shall be included if the
statement is filed pursuant to Rule 13d-1(c):

?By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above
were not acquired and are not held for the purpose of
or with the effect of changing or influencing the
control of the issuer of the securities and were not
acquired and are not held in connection with or as a
participant in any transaction having such purpose or
effect.?



SIGNATURE

After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this
statement is true, complete and correct.


BEAVER CREEK FUND, LTD.
April 18, 2011
(Date)


/s/ Andrew Midler
(Signature)


Andrew Midler ? General Partner
(Name/Title)

ANDREW MIDLER
April 18, 2011
(Date)


/s/ Andrew Midler
(Signature)


Andrew Midler ? General Partner
(Name/Title)


The original statement shall be signed by each person on whose
behalf the statement is filed or his authorized representative.
If the statement is signed on behalf of a person by his
authorized representative other than an executive officer or
general partner of the filing person, evidence of the
representative's authority to sign on behalf of such person
shall be filed with the statement, provided, however, that a
power of attorney for this purpose which is already on file with
the Commission may be incorporated by reference. The name and
any title of each person who signs the statement shall be typed
or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all
exhibits. See ss.240.13d-7 for other parties for whom copies are
to be sent.

Attention: Intentional misstatements or omissions of fact
constitute Federal criminal violations (See 18 U.S.C. 1001)